DOCSLIB.ORG

Muscleblind-Like 2 Controls the Hypoxia Response of Cancer Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Muscleblind-Like 2 Controls the Hypoxia Response of Cancer Cells Downloaded from rnajournal.cshlp.org on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press Muscleblind-like 2 controls the hypoxia response of cancer cells SANDRA FISCHER,1 ANTONELLA DI LIDDO,2 KATARZYNA TAYLOR,3 JAMINA S. GERHARDUS,1 KRZYSZTOF SOBCZAK,3 KATHI ZARNACK,2 and JULIA E. WEIGAND1 1Department of Biology, Technical University of Darmstadt, Darmstadt, 64287, Germany 2Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, 60438, Germany 3Department of Gene Expression, Institute of Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University, Poznan, 61-614, Poland ABSTRACT Hypoxia is a hallmark of solid cancers, supporting proliferation, angiogenesis, and escape from apoptosis. There is still lim- ited understanding of how cancer cells adapt to hypoxic conditions and survive. We analyzed transcriptome changes of human lung and breast cancer cells under chronic hypoxia. Hypoxia induced highly concordant changes in transcript abun- dance, but divergent splicing responses, underlining the cell type-specificity of alternative splicing programs. While RNA- binding proteins were predominantly reduced, hypoxia specifically induced muscleblind-like protein 2 (MBNL2). Strikingly, MBNL2 induction was critical for hypoxia adaptation by controlling the transcript abundance of hypoxia response genes, such as vascular endothelial growth factor A (VEGFA). MBNL2 depletion reduced the proliferation and migration of cancer cells, demonstrating an important role of MBNL2 as cancer driver. Hypoxia control is specific for MBNL2 and not shared by its paralog MBNL1. Thus, our study revealed MBNL2 as central mediator of cancer cell responses to hypoxia, regulating the expression and alternative splicing of hypoxia-induced genes. Keywords: hypoxia; cancer; MBNL2; HIF target genes; alternative splicing INTRODUCTION Semenza 2016). Thus, tumor hypoxia signifies a more ag- gressive phenotype resulting from increased growth and Hypoxia is a common feature of solid tumors as the oxygen metastasis. Moreover, tumor hypoxia counteracts radio-, supply to the rapidly proliferating cancer cells is inade- chemo-, and immunotherapy, highlighting the importance quate. Two types of tumor hypoxia occur as a result of of developing effective hypoxia-targeted therapies structurally and functionally abnormal tumor vasculature. (Graham and Unger 2018). Well studied is the role of the “Chronic” hypoxia arises in cancer cells that are too far HIF (hypoxia inducible factor) transcription factors in the away from the blood vessels to be supplied with sufficient adaptation to hypoxia. HIFs are heterodimers consisting oxygen by diffusion. “Acute” hypoxia is the result of tem- of an oxygen-labile α subunit and a constitutively stable porarily limited perfusion by immature tumor vessels β subunit. Under hypoxia, HIFα subunits are stabilized, al- (Vaupel et al. 2004). Such hypoxic regions are spatially lowing for the transcriptional activation of several hundred and temporally dynamic due to tumor angiogenesis and target genes (Samanta and Semenza 2018). the reversibility of acute hypoxia, resulting in severe intra- Independent from transcriptional adaptation, hypoxia and intertumoral heterogeneity of cellular oxygen levels. triggers a widespread post-transcriptional response by The oxygen content in hypoxic areas of solid tumors is typ- altering alternative splicing (AS) decisions, translation effi- ically <1.4% and may reach complete anoxia (Vaupel et al. ciency, and mRNA stability. For example, at low glucose 2007). conditions, several mRNAs of HIF target genes are stabi- Hypoxia promotes virtually every step in tumor pro- lized under hypoxia (Carraway et al. 2017; Fry et al. gression contributing to metabolic reprogramming, 2017). While canonical protein synthesis is reduced due angiogenesis, extracellular matrix remodeling, epithelial to mesenchymal transition, cancer stem cell maintenance, immune evasion, and cell death resistance (Schito and © 2020 Fischer et al. This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 Corresponding author: [email protected] months, it is available under a Creative Commons License Article is online at http://www.rnajournal.org/cgi/doi/10.1261/rna. (Attribution-NonCommercial 4.0 International), as described at http:// 073353.119. creativecommons.org/licenses/by-nc/4.0/. 648 RNA (2020) 26:648–663; Published by Cold Spring Harbor Laboratory Press for the RNA Society Downloaded from rnajournal.cshlp.org on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press MBNL2 drives hypoxia adaptation to the limited ATP supply during hypoxia, alternative trans- knockdown of MBNL2 in cancer cells leads to reduced pro- lation pathways are activated, to sustain translation of pro- liferation and migration, emphasizing MBNL2 as a driver of teins essential for hypoxia adaptation (for review, see Chee cancer cell function in hypoxia. et al. 2019). Remarkably, ribosomal profiling of hypoxic primary hepatocytes showed that changes in translation RESULTS even precede the transcriptional response (Hettiarachchi et al. 2019). In addition, hypoxia-driven AS events diversify Chronic hypoxia induces similar changes in transcript the cellular response to hypoxia, both in primary and can- abundance, but divergent alternative splicing cerous cells (Weigand et al. 2012; Hu et al. 2014; Brady programs et al. 2017; Han et al. 2017; Bowler et al. 2018). The current knowledge of the factors that control these post-transcrip- We chose A549 lung and MCF-7 breast cancer cells to tional pathways is still very limited, but crucial in under- compare transcriptomic changes in response to chronic standing the tumor-promoting effects of hypoxia. hypoxia, as both cell lines have no deletions or mutations In line with the central role of RNA-binding proteins within the HIF pathway, the two major families of splicing (RBPs) in post-transcriptional gene control, aberrant RBP factors, the SR proteins (serin/arginine rich) and hnRNPs activities have been identified as potent cancer drivers (heterogeneous nuclear ribonucleoproteins) or core spli- (for reviews, see Anczuków and Krainer 2016; Pereira ceosomal genes, such as mutations in SF3B1 (splicing fac- et al. 2017). Just recently, MBNL proteins were found to af- tor 3B1), which are common in cancer (Cerami et al. 2012; fect tumorigenesis (Perron et al. 2018; Tabaglio et al. Gao et al. 2013; Seiler et al. 2018). First, we identified the 2018). The MBNL family consists of the three closely relat- lowest oxygen concentration that would allow continued ed paralogs, MBNL1, MBNL2, and MBNL3 (for review, see survival under hypoxic stress. We incubated A549 and Konieczny et al. 2014). MBNL1 and MBNL2 are ubi- MCF-7 cells for 48 h at two different oxygen levels, 0.5% quitously expressed, whereas MBNL3 expression is more and 0.2% O2. Cell viability after hypoxia treatment was restricted, with highest levels found in the placenta (Far- compared to normoxic (21% O2) controls using crystal vio- daei et al. 2002). All three MBNL paralogs encode two ami- let staining. While incubation at 0.5% O2 showed no differ- no-terminal tandem zinc finger (ZnF) domains. These bind ence in cell viability between normoxic and hypoxic cells to RNAs containing two or more clustered 5′-YGCY-3′ mo- (Fig. 1A), lower oxygen levels of 0.2% significantly reduced tifs (Lambert et al. 2014). The ability of MBNLs to bind RNA the viability of both cell types (Supplemental Fig. 1). is further altered by the structural context of the RNA tar- Further, VEGFA mRNA levels were quantified to control gets (deLorimier et al. 2017; Taylor et al. 2018). Binding for the induction of hypoxia response genes after 48 h at of MBNLs activates or represses mRNA alternative splicing 0.5% O2. VEGFA is a widely expressed, primary target of depending on MBNL binding location (Charizanis et al. HIF transcription factors and thus, a commonly used mark- 2012; Wang et al. 2012), with MBNL1 being the most po- er for the hypoxia response of cells (Forsythe et al. 1996; tent splicing regulator among the three paralogs (Sznajder Blancher et al. 2000). RT-qPCR confirmed a 3.6-fold or et al. 2016). Additionally, MBNL proteins are proposed to 7.2-fold increase in VEGFA mRNA levels in A549 and regulate mRNA stability (Masuda et al. 2012) and localiza- MCF-7 cells, respectively (Fig. 1B). Thus, incubation at tion (Adereth et al. 2005; Wang et al. 2012), alternative 0.5% O2 for 48 h robustly induces a hypoxia response in polyadenylation (Batra et al. 2014), and miRNA biogenesis both cell types without causing cell death and was there- (Rau et al. 2011). All three MBNL proteins undergo auto- fore used for all further experiments. regulatory feedback loops and can functionally compen- For the transcriptome-wide comparison of hypoxia re- sate each other in some cases (Konieczny et al. 2018). sponses, total RNA was extracted from normoxic and hyp- In order to identify RBPs central to the post-tran- oxic A549 and MCF-7 cells, depleted from ribosomal RNA scriptional response of cancer cells during hypoxia, we and subjected to deep sequencing (n = 2). Approximately obtained a comparative set of hypoxia-driven changes in 100 million reads were obtained for each sample. We de- gene and isoform expression as well as changes in RBP lev- tected expression of 18,214 genes
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • MBNL1 Regulates Essential Alternative RNA Splicing Patterns in MLL-Rearranged Leukemia
    ARTICLE https://doi.org/10.1038/s41467-020-15733-8 OPEN MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia Svetlana S. Itskovich1,9, Arun Gurunathan 2,9, Jason Clark 1, Matthew Burwinkel1, Mark Wunderlich3, Mikaela R. Berger4, Aishwarya Kulkarni5,6, Kashish Chetal6, Meenakshi Venkatasubramanian5,6, ✉ Nathan Salomonis 6,7, Ashish R. Kumar 1,7 & Lynn H. Lee 7,8 Despite growing awareness of the biologic features underlying MLL-rearranged leukemia, 1234567890():,; targeted therapies for this leukemia have remained elusive and clinical outcomes remain dismal. MBNL1, a protein involved in alternative splicing, is consistently overexpressed in MLL-rearranged leukemias. We found that MBNL1 loss significantly impairs propagation of murine and human MLL-rearranged leukemia in vitro and in vivo. Through transcriptomic profiling of our experimental systems, we show that in leukemic cells, MBNL1 regulates alternative splicing (predominantly intron exclusion) of several genes including those essential for MLL-rearranged leukemogenesis, such as DOT1L and SETD1A.Wefinally show that selective leukemic cell death is achievable with a small molecule inhibitor of MBNL1. These findings provide the basis for a new therapeutic target in MLL-rearranged leukemia and act as further validation of a burgeoning paradigm in targeted therapy, namely the disruption of cancer-specific splicing programs through the targeting of selectively essential RNA binding proteins. 1 Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 2 Cancer and Blood Diseases Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 3 Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA.
    [Show full text]
  • Accepted By:- Signature Redacted Department of Biology Graduate Co-Chair: Michael T
    EXPLORING THE FUNCTIONAL CONSERVATION OF MUSCLEBLIND (MBL) PROTEINS by MASSACH USETTS INSTITUTE Julia C. Oddo d o ECHNOLOGY B.S. Molecular, Cellular, and Developmental Biology, SE 1 7 2015 Minor Biochemistry 2011 LIB RARIES SUBMITTED TO THE DEPARTMENT OF BIOLOGY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTERS OF SCIENCE IN BIOLOGY AT THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY SEPTEMBER 2015 C 2015 Massachusetts Institute of Technology. All rights reserved. The author hereby grants to MIT permission to reproduce and to distribute publicly paper and electronic copies of this thesis document in whole or in part in any medium now known or hereafter created. Signature redacted Signature of Auth or:_ Department of Biology May 22, 2015 Certified by: Signature redacte Thesis Supervisor: Chris B. Burge Professor of Biology and Biological Engineering Director Program CSB Certified by: Signature redactec Thesis Co-Supervisor: Eric T. Wang Research Fellow Accepted by:- Signature redacted Department of Biology Graduate Co-Chair: Michael T. Hemann Associate Professor of Biology 1 EXPLORING THE FUNCTIONAL CONSERVATION OF MUSCLEBLIND (MBL) PROTEINS by Julia C. Oddo Submitted to the Department of Biology on September 8th, 2015 in Partial Fulfillment of the Requirements for the Degree of Master of Science in Biology ABSTRACT Muscleblind (Mbl) is an evolutionarily conserved family of proteins involved in many aspects of RNA metabolism, including alternative splicing. Disruption of Muscleblind in several animals lends to a variety of defects and disease, including the multi-systemic disorder Myotonic Dystrophy (DM). Though much is known about the involvement of Muscleblind in DM, there is much basic knowledge of the protein's function to be discovered.
    [Show full text]
  • Role and Regulation of the P53-Homolog P73 in the Transformation of Normal Human Fibroblasts
    Role and regulation of the p53-homolog p73 in the transformation of normal human fibroblasts Dissertation zur Erlangung des naturwissenschaftlichen Doktorgrades der Bayerischen Julius-Maximilians-Universität Würzburg vorgelegt von Lars Hofmann aus Aschaffenburg Würzburg 2007 Eingereicht am Mitglieder der Promotionskommission: Vorsitzender: Prof. Dr. Dr. Martin J. Müller Gutachter: Prof. Dr. Michael P. Schön Gutachter : Prof. Dr. Georg Krohne Tag des Promotionskolloquiums: Doktorurkunde ausgehändigt am Erklärung Hiermit erkläre ich, dass ich die vorliegende Arbeit selbständig angefertigt und keine anderen als die angegebenen Hilfsmittel und Quellen verwendet habe. Diese Arbeit wurde weder in gleicher noch in ähnlicher Form in einem anderen Prüfungsverfahren vorgelegt. Ich habe früher, außer den mit dem Zulassungsgesuch urkundlichen Graden, keine weiteren akademischen Grade erworben und zu erwerben gesucht. Würzburg, Lars Hofmann Content SUMMARY ................................................................................................................ IV ZUSAMMENFASSUNG ............................................................................................. V 1. INTRODUCTION ................................................................................................. 1 1.1. Molecular basics of cancer .......................................................................................... 1 1.2. Early research on tumorigenesis ................................................................................. 3 1.3. Developing
    [Show full text]
  • Alternative Splicing in the Nuclear Receptor Superfamily Expands Gene Function to Refine Endo-Xenobiotic Metabolism S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2020/01/24/dmd.119.089102.DC1 1521-009X/48/4/272–287$35.00 https://doi.org/10.1124/dmd.119.089102 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 48:272–287, April 2020 Copyright ª 2020 by The American Society for Pharmacology and Experimental Therapeutics Minireview Alternative Splicing in the Nuclear Receptor Superfamily Expands Gene Function to Refine Endo-Xenobiotic Metabolism s Andrew J. Annalora, Craig B. Marcus, and Patrick L. Iversen Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon (A.J.A., C.B.M., P.L.I.) and United States Army Research Institute for Infectious Disease, Frederick, Maryland (P.L.I.) Received August 16, 2019; accepted December 31, 2019 ABSTRACT Downloaded from The human genome encodes 48 nuclear receptor (NR) genes, whose Exon inclusion options are differentially distributed across NR translated products transform chemical signals from endo- subfamilies, suggesting group-specific conservation of resilient func- xenobiotics into pleotropic RNA transcriptional profiles that refine tionalities. A deeper understanding of this transcriptional plasticity drug metabolism. This review describes the remarkable diversifica- expands our understanding of how chemical signals are refined and tion of the 48 human NR genes, which are potentially processed into mediated by NR genes. This expanded view of the NR transcriptome over 1000 distinct mRNA transcripts by alternative splicing (AS). The informs new models of chemical toxicity, disease diagnostics, and dmd.aspetjournals.org average human NR expresses ∼21 transcripts per gene and is precision-based approaches to personalized medicine.
    [Show full text]
  • The Alternative Splicing Factor MBNL1 Inhibits Glioblastoma Tumor Initiation and Progression by Reducing Hypoxia-Induced Stemness
    Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/0008-5472.CAN-20-1233 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. The Alternative Splicing Factor MBNL1 Inhibits Glioblastoma Tumor Initiation and Progression by Reducing Hypoxia-induced Stemness Dillon M. Voss1*, Anthony Sloan1*, Raffaella Spina, PhD2,3,4, Heather M. Ames, MD PhD2,4, and Eli E. Bar, PhD2,3,4 1 Department of Neurological Surgery, Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America. 2 Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America. 3 Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, United States of America. 4 Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United States of America. *Authors contributed equally to the study Running Title: MBNL1 Regulates GBM Initiation and Progression The authors declare no potential conflicts of interest. Correspondence to: Eli E. Bar, Ph.D. Departments of Pathology and Neurosurgery, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine 655 W. Baltimore St., Bressler Research Bldg., Room 8-039, Baltimore, MD 21201; [email protected] (office) 410-706-4826, (lab) 410-706- 2299 Word Count: 7946 1 Downloaded from cancerres.aacrjournals.org on September 23, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on September 14, 2020; DOI: 10.1158/0008-5472.CAN-20-1233 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • 1 Transcriptionally-Correlated Sub-Cellular Dynamics of MBNL1
    Transcriptionally-correlated sub-cellular dynamics of MBNL1 during lens development and their implication for the molecular pathology of Myotonic Dystrophy Type 1. Stewart M. Coleman*, Alan, R. Prescott†, Judith E. Sleeman*. *University of St Andrews, School of Biology, BSRC Complex, North Haugh, St Andrews, UK, KY16 9ST. †University of Dundee, College of Life Sciences, Dundee, UK, DD1 5EH. Corresponding author: Judith E Sleeman, University of St Andrews, School of Biology, BSRC Complex, North Haugh, St Andrews, UK, KY16 9ST. Tel: +44 (0)1334 463524, [email protected]. 1 1 Abbreviations: ASF, alternative splicing factor; 5-BrU, 5-bromouridine; Cy5, cyanine 5; DM1, Myotonic Dystrophy Type 1; DMEM, Dulbecco’s modification of Eagle’s medium; DMPK, dystrophia myotonica protein kinase; DRB 5,6-Dichloro-1-β-D- ribofuranosylbenzimidazole; FISH, fluorescent in situ hybridization; HLE, human lens epithelial; LEC, lens epithelial cell; MBNL1, muscleblind-like protein 1; PAGFP, photoactivatable GFP; PFA, paraformaldehyde; SC35, splicing component 35kDa; snoRNP, small nucleolar ribonucleoprotein; snRNP, small nuclear ribonucleoprotein; SSA, spliceostatin A; SSC, saline sodium citrate. 1 Abstract Myotonic Dystrophy Type 1 (DM1) is caused by elongation of a CTG repeat in the dystrophia myotonica protein kinase (DMPK) gene. mRNA transcripts containing the resulting CUGexp repeats form accumulations, or foci, in the nucleus of the cell. The pathogenesis of Myotonic dystrophy type 1 (DM1) is proposed to result from inappropriate patterns of alternative splicing caused by sequestration of the developmentally regulated alternative splicing factor muscleblind-like 1 (MBNL1), by these foci. Since eye lens cataract is a common feature of DM1 we have examined the distribution and dynamics of MBNL1 in lens epithelial cell lines derived from DM1 patients.
    [Show full text]
  • Identification of Protein Features Encoded by Alternative Exons Using Exon Ontology
    Downloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Resource Identification of protein features encoded by alternative exons using Exon Ontology Léon-Charles Tranchevent,1 Fabien Aubé,1 Louis Dulaurier,1 Clara Benoit-Pilven,1 Amandine Rey,1 Arnaud Poret,1 Emilie Chautard,2 Hussein Mortada,1 François-Olivier Desmet,1 Fatima Zahra Chakrama,1 Maira Alejandra Moreno-Garcia,1 Evelyne Goillot,3 Stéphane Janczarski,1 Franck Mortreux,1 Cyril F. Bourgeois,1,4 and Didier Auboeuf1,4 1Université Lyon 1, ENS de Lyon, CNRS UMR 5239, INSERM U1210, Laboratory of Biology and Modelling of the Cell, F-69007, Lyon, France; 2Laboratoire de Biométrie et Biologie Évolutive, Université Lyon 1, UMR CNRS 5558, INRIA Erable, Villeurbanne, F-69622, France; 3Institut NeuroMyoGène, CNRS UMR 5310, INSERM U1217, Université Lyon 1, Lyon, F-69007 France Transcriptomic genome-wide analyses demonstrate massive variation of alternative splicing in many physiological and pathological situations. One major challenge is now to establish the biological contribution of alternative splicing var- iation in physiological- or pathological-associated cellular phenotypes. Toward this end, we developed a computational approach, named Exon Ontology, based on terms corresponding to well-characterized protein features organized in an ontology tree. Exon Ontology is conceptually similar to Gene Ontology-based approaches but focuses on exon-encod- ed protein features instead of gene level functional annotations. Exon Ontology describes the protein features encoded by a selected list of exons and looks for potential Exon Ontology term enrichment. By applying this strategy to exons that are differentially spliced between epithelial and mesenchymal cells and after extensive experimental validation, we demonstrate that Exon Ontology provides support to discover specific protein features regulated by alternative splic- ing.
    [Show full text]
  • The Protein Factors MBNL1 and U2AF65 Bind Alternative RNA Structures to Regulate Splicing
    The protein factors MBNL1 and U2AF65 bind alternative RNA structures to regulate splicing M. Bryan Warf, Julien V. Diegel, Peter H. von Hippel, and J. Andrew Berglund1 Institute of Molecular Biology and Department of Chemistry, University of Oregon, Eugene, OR 97403 Edited by Michael Rosbash, Brandeis University, Waltham, MA, and approved April 14, 2009 (received for review January 14, 2009) Myotonic dystrophy type 1 (DM1) is a genetic disorder linked to a snRNP, the spliceosome selects another 3Ј splice site, or the CTG)n repeat expansion in the 3؅ untranslated region of the DMPK intron is retained if another 3Ј splice site cannot be defined) gene. Upon transcription in the nucleus, the CUG repeats form a (13, 14). stable RNA stem-loop that sequesters the RNA-binding protein We hypothesized that MBNL1 may act through a similar MBNL1 from its normal function in the cell. MBNL1 regulates the mechanism to compete with U2AF65. U2AF65 is a potential alternative splicing of many pre-mRNAs, and upon MBNL1’s competitive target of MBNL1 because a putative U2AF65 sequestration, the alternative splicing of many genes is mis- binding site appears to be in the loop portion of the stem-loop regulated, leading to disease symptoms. MBNL1 is known to bind which MBNL1 binds (5). We found that MBNL1 does compete directly to at least 3 of the pre-mRNAs that it regulates, but how with U2AF65 for binding of a region within intron 4. This MBNL1 binding mechanistically regulates alternative splicing is competition with U2AF65 is functionally important, because unclear. Here, we demonstrate that MBNL1 controls the splicing of recruitment of the U2 snRNP is reduced by MBNL1.
    [Show full text]
  • Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer
    Epigenetic mechanisms are involved in the oncogenic properties of ZNF518B in colorectal cancer Francisco Gimeno-Valiente, Ángela L. Riffo-Campos, Luis Torres, Noelia Tarazona, Valentina Gambardella, Andrés Cervantes, Gerardo López-Rodas, Luis Franco and Josefa Castillo SUPPLEMENTARY METHODS 1. Selection of genomic sequences for ChIP analysis To select the sequences for ChIP analysis in the five putative target genes, namely, PADI3, ZDHHC2, RGS4, EFNA5 and KAT2B, the genomic region corresponding to the gene was downloaded from Ensembl. Then, zoom was applied to see in detail the promoter, enhancers and regulatory sequences. The details for HCT116 cells were then recovered and the target sequences for factor binding examined. Obviously, there are not data for ZNF518B, but special attention was paid to the target sequences of other zinc-finger containing factors. Finally, the regions that may putatively bind ZNF518B were selected and primers defining amplicons spanning such sequences were searched out. Supplementary Figure S3 gives the location of the amplicons used in each gene. 2. Obtaining the raw data and generating the BAM files for in silico analysis of the effects of EHMT2 and EZH2 silencing The data of siEZH2 (SRR6384524), siG9a (SRR6384526) and siNon-target (SRR6384521) in HCT116 cell line, were downloaded from SRA (Bioproject PRJNA422822, https://www.ncbi. nlm.nih.gov/bioproject/), using SRA-tolkit (https://ncbi.github.io/sra-tools/). All data correspond to RNAseq single end. doBasics = TRUE doAll = FALSE $ fastq-dump -I --split-files SRR6384524 Data quality was checked using the software fastqc (https://www.bioinformatics.babraham. ac.uk /projects/fastqc/). The first low quality removing nucleotides were removed using FASTX- Toolkit (http://hannonlab.cshl.edu/fastxtoolkit/).
    [Show full text]
  • ID AKI Vs Control Fold Change P Value Symbol Entrez Gene Name *In
    ID AKI vs control P value Symbol Entrez Gene Name *In case of multiple probesets per gene, one with the highest fold change was selected. Fold Change 208083_s_at 7.88 0.000932 ITGB6 integrin, beta 6 202376_at 6.12 0.000518 SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 1553575_at 5.62 0.0033 MT-ND6 NADH dehydrogenase, subunit 6 (complex I) 212768_s_at 5.50 0.000896 OLFM4 olfactomedin 4 206157_at 5.26 0.00177 PTX3 pentraxin 3, long 212531_at 4.26 0.00405 LCN2 lipocalin 2 215646_s_at 4.13 0.00408 VCAN versican 202018_s_at 4.12 0.0318 LTF lactotransferrin 203021_at 4.05 0.0129 SLPI secretory leukocyte peptidase inhibitor 222486_s_at 4.03 0.000329 ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 1552439_s_at 3.82 0.000714 MEGF11 multiple EGF-like-domains 11 210602_s_at 3.74 0.000408 CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 229947_at 3.62 0.00843 PI15 peptidase inhibitor 15 204006_s_at 3.39 0.00241 FCGR3A Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 202238_s_at 3.29 0.00492 NNMT nicotinamide N-methyltransferase 202917_s_at 3.20 0.00369 S100A8 S100 calcium binding protein A8 215223_s_at 3.17 0.000516 SOD2 superoxide dismutase 2, mitochondrial 204627_s_at 3.04 0.00619 ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 223217_s_at 2.99 0.00397 NFKBIZ nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta 231067_s_at 2.97 0.00681 AKAP12 A kinase (PRKA) anchor protein 12 224917_at 2.94 0.00256 VMP1/ mir-21likely ortholog
    [Show full text]
  • Towards Personalized Medicine in Psychiatry: Focus on Suicide
    TOWARDS PERSONALIZED MEDICINE IN PSYCHIATRY: FOCUS ON SUICIDE Daniel F. Levey Submitted to the faculty of the University Graduate School in partial fulfillment of the requirements for the degree Doctor of Philosophy in the Program of Medical Neuroscience, Indiana University April 2017 ii Accepted by the Graduate Faculty, Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Andrew J. Saykin, Psy. D. - Chair ___________________________ Alan F. Breier, M.D. Doctoral Committee Gerry S. Oxford, Ph.D. December 13, 2016 Anantha Shekhar, M.D., Ph.D. Alexander B. Niculescu III, M.D., Ph.D. iii Dedication This work is dedicated to all those who suffer, whether their pain is physical or psychological. iv Acknowledgements The work I have done over the last several years would not have been possible without the contributions of many people. I first need to thank my terrific mentor and PI, Dr. Alexander Niculescu. He has continuously given me advice and opportunities over the years even as he has suffered through my many mistakes, and I greatly appreciate his patience. The incredible passion he brings to his work every single day has been inspirational. It has been an at times painful but often exhilarating 5 years. I need to thank Helen Le-Niculescu for being a wonderful colleague and mentor. I learned a lot about organization and presentation working alongside her, and her tireless work ethic was an excellent example for a new graduate student. I had the pleasure of working with a number of great people over the years. Mikias Ayalew showed me the ropes of the lab and began my understanding of the power of algorithms.
    [Show full text]